Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Spontaneous Osteonecrosis of the Knee
NCT00477217Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Jan 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zoledronic acid in Osteonecrosis of the knee (SONK), sponsored by Novartis. Planned start Jan 2008; status: withdrawn.
02
Drugs
zoledronic acid
03
Conditions
Osteonecrosis of the knee (SONK)
Beyond the preview
Go deeper on NCT00477217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00477217.